As a CE provider, the ACR has a responsibility to provide REMS education to prescribers. As the ACR’s first step in live REMS CME, Dr. Gibofsky will give a presentation entitled, “Evaluation and Mitigation Strategy for Extended-Release and Long-Acting Opioid Analgesics,” at the 2013 State-of-the-Art Clinical Symposium in Chicago. During his talk, Dr. Gibofsky will explain the magnitude of use of ER/LA opioids and walk attendees through the FDA REMS on these drugs. While it is not obligatory for prescribers to attend REMS sessions, Dr. Gibofsky believes it is important for prescribers to receive this training because, he says, “extended-release and long-acting opioid medications can cause specific safety problems, even when they are appropriately prescribed.”
This session recording will be available to all ACR/ARHP members at no charge via SessionSelect after the meeting.
References
- Questions and Answers: FDA approves a Risk Evaluation and Mitigation Strategy (REMS) for Extended-Release and Long-Acting (ER/LA) Opioid Analgesics. U.S. Food and Drug Administration. Available at www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm309742.htm. Updated July 14, 2012. Accessed February 19, 2013.
- FDA introduces new safety measures for extended-release and long-acting opioid medications [news release]. Silver Spring, MD: U.S. Food and Drug Administration. Available at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310870.htm. Published July 9, 2012. Accessed February 19, 2013.
- FDA Works to Reduce Risk of Opioid Pain Relievers. Available at www.fda.gov/forconsumers/consumerupdates/ucm307821.htm. Updated July 7, 2012. Accessed February 19, 2013.
